

Table S1: Baseline characteristics of the subcohort with follow-up ≥ 33 months (N=5315)

		TOTAL (N= 5135)	NO DM (N= 5123)	DM (N= 192)	p
BASELINE VARIABLES					
Female sex ^(b)		676 (12.7)	649 (12.7)	27 (14.1)	0.58
Age ^(a)		36.5 (29.9-44.5)	36.1 (29.7-43.8)	46.3 (39-54.4)	<0.001
CD4 (cells/ μ L) ^(a)		355 (207-508)	358 (210.5-509)	295.5 (105-449)	<0.001
Body mass index ^(a)		23.5 (21.5-25.8)	23.4 (21.5-25.6)	26.6 (23.5-29.6)	<0.001
Months between diagnosis of HIV and initiation of ART ^(a)			3.4 (1.3-14.1)	1.7 (0.8-7.6)	<0.001
Route of infection ^(b)	MSM	3561 (69.2)	3464 (69.8)	97 (53.3)	(c)
	IDU	196 (3.8)	180 (3.6)	16 (8.8)	(c)
	Heterosexual relations	1356 (26.4)	1293 (26.1)	63 (34.6)	(c)
	Other	30 (0.6)	24 (0.5)	6 (3.3)	<0.001 (c)
Origin ^(b)	Sub-Saharan Africa	174 (3.3)	161 (3.1)	13 (6.8)	(c)
	Spain	3264 (61.4)	3157 (61.6)	107 (55.7)	
	Europe	779 (14.7)	734 (14.3)	45 (23.4)	(c)
	Latin America/Caribbean	977 (18.4)	956 (18.7)	21 (10.9)	(c)
	North Africa	47 (0.9)	45 (0.9)	2 (1)	
	Other	74 (1.4)	70 (1.4)	4 (2.1)	<0.001
Longest time in education ^(b)	Basic secondary	1482 (33.6)	1402 (33)	80 (51)	(c)
	Pre-university/Trade school	1459 (33.1)	1416 (33.3)	43 (27.4)	
	University/Higher	1470 (33.3)	1436 (33.8)	34 (21.7)	<0.001 (c)
HCV before initiating ART ^(b)			322 (6.6)	25 (13.5)	0.001
Corticosteroids and/or bronchodilators before ART ^(b)			25 (0.5)	2 (1.0)	0.25
Non-AIDS related events before before ART ^(b)		356 (6.7)	347 (6.8)	9 (4.7)	0.3
Cardiovascular Non-AIDS related events before before ART ^(b)		37 (0.7)	31 (0.6)	6 (3.1)	<0.01
AIDS before ART ^(b)		562 (10.6)	523 (10.2)	39 (20.3)	<0.001
First ART regimen ^(b)	2NRTI+1NNRTI	2107 (39.6)	2040 (39.8)	67 (34.9)	

2NRTI+1PI	1182 (22.2)	1138 (22.2)	44 (22.9)	
2NRTI+1II	1735 (32.6)	1668 (32.6)	67 (34.9)	
Other	291 (5.5)	277 (5.4)	14 (7.3)	0.44

FOLLOW-UP ^(d) VARIABLES

Interruption first ART regimen ^(b)	4146 (78)	4030 (78.7)	116 (60.4)	<0.001
Time (months) on ART ^(a)	59.3 (44-78)	60 (45-79)	27 (8-50)	<0.001
Death (total) ^(b)	68 (1.3)	58 (1.1)	10 (5.2)	<0.001
Loss to follow-up (total) ^(b)	266 (5.0)	255 (5.0)	11 (5.7)	0.61
Months of follow-up (total) ^(a)	61 (46.2-80.3)	60.9 (46.2-79.8)	64.8 (40.7-90.1)	0.44
Months until diagnosis of T2DM ^(a)	---	---	27.5 (8.2-50.9)	---

^a Median (interquartile range)

^b N (%)

^c Differences (p<0.05) in multiple comparisons

^d Censored at diagnosis of T2DM or at 31-12-2019 if no T2DM

Total: including time after the diagnosis of T2DM